Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases.
O
O
Dereure
B
B
Guillot
C
C
Jorgensen
J-D
JD
Cohen
B
B
Combes
J-J
JJ
Guilhou
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D007868:Leg Dermatoses / Q000139:chemically induced; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept